{"name":"TUMOR","title":"","children":[{"id":"breast","name":"breast","presenterLast":"breast","children":[{"id":3522,"name":"breast_3522","title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"colorectal","name":"colorectal","presenterLast":"colorectal","children":[{"id":2082,"name":"colorectal_2082","title":"Novel small-molecule inhibitor of PD1/PDL1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy","presenterFirst":"Yuguang","presenterLast":"Wang","keywords":"Immunotherapy;Small molecule PD1/PDL1 inhibitor;anti-CTLA4;Epacadostat","target":"PD1/L1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2290,"name":"colorectal_2290","title":"Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody","presenterFirst":"Yosuke","presenterLast":"Ota","keywords":"Combination therapy;TLR7;PD-1;memory T cell","target":"TLR7","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2320,"name":"colorectal_2320","title":"Depletion of blood arginine with pegzilarginase (AEB1102) in combination with anti-PD-L1 increases tumor infiltration by immune cells and enhances antitumor activity","presenterFirst":"Giulia","presenterLast":"Agnello","keywords":"Arginine deprivation;Tumor microenvironment;Metabolism;Checkpoint inhibitors","target":"arginase1","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2544,"name":"colorectal_2544","title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2562,"name":"colorectal_2562","title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3070,"name":"colorectal_3070","title":"Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models","presenterFirst":"Daqing","presenterLast":"Wang","keywords":"Immunotherapy;Tumor microenvironment;Immunomodulation;Combination therapy","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3522,"name":"colorectal_3522","title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3759,"name":"colorectal_3759","title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":4634,"name":"colorectal_4634","title":"Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer","presenterFirst":"Dhanalakshmi","presenterLast":"Sivanandhan","keywords":"Small molecule inhibitor;Epigenetics","target":"LSD1_HDAC","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5025,"name":"colorectal_5025","title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5170,"name":"colorectal_5170","title":"Metabolic modulation of the tumor microenvironment using Synthetic Biotic\u2122 Medicines","presenterFirst":"Kip","presenterLast":"West","keywords":"Immunotherapy;Immunomodulation;Tumor microenvironment;Bacterial treatment","target":"KYN","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6343,"name":"colorectal_6343","title":"4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches","presenterFirst":"Svetlana","presenterLast":"Hamm","keywords":"Histone deacetylase inhibitor;Combination therapy;Checkpoint","target":"HDAC","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7423,"name":"colorectal_7423","title":"Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival","presenterFirst":"James","presenterLast":"Campbell","keywords":"Chemokine receptor;Colorectal cancer;Checkpoint;Gastrointestinal cancers: colorectal","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7608,"name":"colorectal_7608","title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"gastric","name":"gastric","presenterLast":"gastric","children":[{"id":7441,"name":"gastric_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"gastric","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"hcc","name":"hcc","presenterLast":"hcc","children":[{"id":2952,"name":"hcc_2952","title":"Identifying characteristics of orthotopic HCC mouse models to predict response to immunotherapy","presenterFirst":"Carina","presenterLast":"Hage","keywords":"Hepatocellular carcinoma;Immunotherapy;Mouse models;Combination therapy","target":"TLR7/8","tumor":"hcc","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"headneck","name":"headneck","presenterLast":"headneck","children":[{"id":7441,"name":"headneck_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"headneck","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"leukemia","name":"leukemia","presenterLast":"leukemia","children":[{"id":3285,"name":"leukemia_3285","title":"Preclinical study of a novel TLR8 selective agonist for cancer immunotherapy","presenterFirst":"Yuxun","presenterLast":"Wang","keywords":"Cancer immunotherapy;Targeted therapy;Innate immunity;Drug discovery","target":"TLR8","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"lymphoma","name":"lymphoma","presenterLast":"lymphoma","children":[{"id":2544,"name":"lymphoma_2544","title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"lymphoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3759,"name":"lymphoma_3759","title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7441,"name":"lymphoma_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"lymphoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"melanoma","name":"melanoma","presenterLast":"melanoma","children":[{"id":10861,"name":"melanoma_10861","title":"Imprime PGG, a soluble yeast \u03b2-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients","presenterFirst":"Mark","presenterLast":"Uhlik","keywords":"Immune response;Imprime PGG;melanoma;Triple negative breast cancer","target":"PAMP","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"clinical"},{"id":2562,"name":"melanoma_2562","title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5025,"name":"melanoma_5025","title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5311,"name":"melanoma_5311","title":"CXCR4 inhibition modulates tumor microenvironment and robustly inhibits growth of B16-OVA melanoma","presenterFirst":"James","presenterLast":"Mier","keywords":"CXCR4;T cell;melanoma","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6137,"name":"melanoma_6137","title":"Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","presenterFirst":"Katharina","presenterLast":"Deschler","keywords":"Innate immunity;Checkpoint;T lymphocytes","target":"TLR7/8","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7521,"name":"melanoma_7521","title":"Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing","presenterFirst":"Kathryn","presenterLast":"Fraser","keywords":"Natural killer cells;Immunotherapy;Antibody","target":"PAMP","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7608,"name":"melanoma_7608","title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"multiple","name":"multiple","presenterLast":"multiple","children":[{"id":6119,"name":"multiple_6119","title":"NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders","presenterFirst":"Izhak","presenterLast":"Haviv","keywords":"Drug resistance;Immunomodulation;Combination therapy;Efficacy","target":"STAT3_IRS1/2","tumor":"multiple","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"NA","name":"NA","presenterLast":"NA","children":[{"id":3556,"name":"NA_3556","title":"Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth","presenterFirst":"Paul","presenterLast":"Kassner","keywords":"Tumor immunity;Regulatory T cell;Deubiquitinase inhibitor;p53","target":"USP7","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical in vitro"},{"id":3846,"name":"NA_3846","title":"Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models","presenterFirst":"Yifan","presenterLast":"Zhai","keywords":"IAP;Checkpoint;Immunotherapy","target":"IAP","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6433,"name":"NA_6433","title":"Identification and characterization of the IDO1 inhibitor LY3381916","presenterFirst":"Frank","presenterLast":"Dorsey","keywords":"Immunomodulation;Small molecule inhibitor;Immunotherapy;Lung cancer","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6912,"name":"NA_6912","title":"Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214","presenterFirst":"Saul","presenterLast":"Kivimae","keywords":"Dendritic cells;Tumor immunity;Cancer immunotherapy;T cell","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7442,"name":"NA_7442","title":"Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine","presenterFirst":"Xiaoyan","presenterLast":"Zhang","keywords":"Immunotherapy;Tumor microenvironment","target":"KYN","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8244,"name":"NA_8244","title":"Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors","presenterFirst":"Sarah","presenterLast":"McWhirter","keywords":"Checkpoint;Cancer immunotherapy;Innate immunity;Tumor microenvironment","target":"STING","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8314,"name":"NA_8314","title":"T-cell activation through the inhibition of tumor-expressed IDO1 activity in tryptophan metabolism pathway","presenterFirst":"Frank","presenterLast":"Xing","keywords":"T cell;IDO1","target":"IDO1","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"ovarian","name":"ovarian","presenterLast":"ovarian","children":[{"id":2325,"name":"ovarian_2325","title":"Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models","presenterFirst":"Sarah","presenterLast":"Wang","keywords":"Combination studies;Checkpoint;PARP;Combination therapy","target":"PARP1/2","tumor":"ovarian","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7250,"name":"ovarian_7250","title":"MPL-5821, a macrophage targeted ESM<sup>TM</sup> p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality","presenterFirst":"David","presenterLast":"Moffat","keywords":"Macrophages;MAP kinase;Immune response;Interleukin-10","target":"MAPK_TLR","tumor":"ovarian","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]}]}
